Orbimed Advisors - Q4 2014 holdings

$10.5 Billion is the total value of Orbimed Advisors's 131 reported holdings in Q4 2014. The portfolio turnover from Q3 2014 to Q4 2014 was 26.9% .

 Value Shares↓ Weighting
BIIB BuyBIOGEN IDEC INC$507,376,000
+28.9%
1,494,700
+25.6%
4.85%
+17.9%
BMY BuyBRISTOL MYERS SQUIBB CO$453,864,000
+21.6%
7,688,700
+5.4%
4.34%
+11.3%
AMGN BuyAMGEN INC$431,357,000
+18.0%
2,708,000
+4.0%
4.12%
+7.9%
CELG BuyCELGENE CORP$409,139,000
+29.7%
3,657,600
+9.9%
3.91%
+18.7%
GILD BuyGILEAD SCIENCES INC$400,558,000
+0.0%
4,249,500
+13.0%
3.83%
-8.5%
B108PS BuyACTAVIS PLC$383,078,000
+10.5%
1,488,200
+3.6%
3.66%
+1.2%
ABBV SellABBVIE INC$348,867,000
+10.3%
5,331,100
-2.7%
3.33%
+0.9%
HCA BuyHCA HOLDINGS INC$316,164,000
+6.4%
4,308,000
+2.3%
3.02%
-2.6%
RLYP  RELYPSA INC$272,813,000
+46.0%
8,857,5510.0%2.61%
+33.6%
ILMN BuyILLUMINA INC$272,551,000
+23.8%
1,476,600
+9.9%
2.60%
+13.3%
SHPG SellSHIRE PLCsponsored adr$248,672,000
-21.3%
1,170,000
-4.0%
2.38%
-28.0%
ISRG BuyINTUITIVE SURGICAL INC$232,734,000
+30.4%
440,000
+13.9%
2.22%
+19.3%
ICPT  INTERCEPT PHARMACEUTICALS IN$231,660,000
-34.1%
1,485,0000.0%2.21%
-39.7%
INCY SellINCYTE CORP$230,245,000
+44.2%
3,149,300
-3.2%
2.20%
+31.9%
MDVN SellMEDIVATION INC$226,005,000
+0.6%
2,268,900
-0.2%
2.16%
-8.0%
IPXL BuyIMPAX LABORATORIES INC$211,559,000
+39.3%
6,678,000
+4.3%
2.02%
+27.5%
PRGO BuyPERRIGO CO PLC$208,582,000
+21.3%
1,247,800
+9.0%
1.99%
+11.0%
VRTX BuyVERTEX PHARMACEUTICALS INC$205,667,000
+35.6%
1,731,200
+28.2%
1.96%
+24.1%
TMO SellTHERMO FISHER SCIENTIFIC INC$199,925,000
-2.9%
1,595,700
-5.7%
1.91%
-11.2%
HNT BuyHEALTH NET INC$198,671,000
+40.3%
3,711,400
+20.9%
1.90%
+28.3%
COO BuyCOOPER COS INC$197,847,000
+11.2%
1,220,600
+6.8%
1.89%
+1.7%
ESRX BuyEXPRESS SCRIPTS HLDG CO$195,334,000
+31.8%
2,307,000
+10.0%
1.87%
+20.6%
MOH BuyMOLINA HEALTHCARE INC$191,739,000
+65.6%
3,581,900
+30.8%
1.83%
+51.4%
IRWD  IRONWOOD PHARMACEUTICALS INC$184,025,000
+18.3%
12,012,1000.0%1.76%
+8.2%
A SellAGILENT TECHNOLOGIES INC$165,848,000
-5.3%
4,051,000
-5.8%
1.58%
-13.4%
MRK BuyMERCK & CO INC NEW$165,560,000
+4.9%
2,915,300
+9.5%
1.58%
-4.0%
REGN BuyREGENERON PHARMACEUTICALS$160,080,000
+20.1%
390,200
+5.6%
1.53%
+9.9%
AGN SellALLERGAN INC$157,593,000
-1.5%
741,300
-17.4%
1.51%
-9.9%
MCK BuyMCKESSON CORP$154,024,000
+11.8%
742,000
+4.8%
1.47%
+2.2%
ZBH BuyZIMMER HLDGS INC$145,484,000
+14.9%
1,282,700
+1.8%
1.39%
+5.1%
NBIX BuyNEUROCRINE BIOSCIENCES INC$133,339,000
+46.9%
5,968,600
+3.0%
1.27%
+34.4%
TRNX  TORNIER N V$122,528,000
+6.7%
4,805,0000.0%1.17%
-2.4%
P103PS BuyNPS PHARMACEUTICALS INC$105,697,000
+55.4%
2,954,900
+13.0%
1.01%
+42.3%
SYK BuySTRYKER CORP$97,311,000
+20.2%
1,031,600
+2.9%
0.93%
+9.9%
PODD BuyINSULET CORP$91,982,000
+27.8%
1,997,000
+2.3%
0.88%
+16.9%
PFE BuyPFIZER INC$85,943,000
+8.9%
2,759,000
+3.3%
0.82%
-0.5%
INFI  INFINITY PHARMACEUTICALS INC$80,006,000
+25.9%
4,736,9000.0%0.76%
+15.2%
OTIC  OTONOMY INC$75,206,000
+38.9%
2,256,3980.0%0.72%
+27.0%
MGLN BuyMAGELLAN HEALTH INC$72,516,000
+229.1%
1,208,000
+200.0%
0.69%
+201.3%
FLDM BuyFLUIDIGM CORP DEL$72,054,000
+40.0%
2,136,200
+1.7%
0.69%
+28.3%
T107PS BuyWRIGHT MED GROUP INC$67,900,000
-8.3%
2,527,000
+3.4%
0.65%
-16.0%
AFFX  AFFYMETRIX INC$64,826,000
+23.7%
6,568,0000.0%0.62%
+13.2%
ALXN BuyALEXION PHARMACEUTICALS INC$61,430,000
+18.7%
332,000
+6.4%
0.59%
+8.7%
MNKKQ BuyMALLINCKRODT PUB LTD CO$56,150,000
+111.9%
567,001
+92.9%
0.54%
+93.9%
SIEN NewSIENTRA INC$53,481,0003,185,308
+100.0%
0.51%
AGN NewALLERGAN INCcall$53,148,000250,000
+100.0%
0.51%
INSYQ BuyINSYS THERAPEUTICS INC NEW$52,413,000
+83.7%
1,243,200
+69.0%
0.50%
+68.1%
JNJ BuyJOHNSON & JOHNSON$51,762,000
+14.8%
495,000
+17.0%
0.50%
+5.1%
NUVA BuyNUVASIVE INC$50,556,000
+119.0%
1,072,000
+61.9%
0.48%
+100.4%
TSRO NewTESARO INC$49,463,0001,330,000
+100.0%
0.47%
EXAS BuyEXACT SCIENCES CORP$48,788,000
+46.1%
1,778,000
+3.2%
0.47%
+33.5%
XNPT  XENOPORT INC$48,639,000
+63.0%
5,546,1000.0%0.46%
+49.0%
PBYI BuyPUMA BIOTECHNOLOGY INC$47,488,000
-6.5%
250,900
+17.8%
0.45%
-14.5%
CERS SellCERUS CORP$43,898,000
+52.4%
7,035,000
-2.1%
0.42%
+39.2%
SPY SellSPDR S&P 500 ETF TRput$41,108,000
-40.4%
200,000
-42.9%
0.39%
-45.4%
CLVS NewCLOVIS ONCOLOGY INC$39,990,000714,100
+100.0%
0.38%
PRQR BuyPROQR THRAPEUTICS N V$39,643,000
+142.7%
1,829,400
+92.6%
0.38%
+121.6%
OPHT BuyOPHTHOTECH CORP$38,669,000
+193.2%
861,800
+154.4%
0.37%
+168.1%
CLDX SellCELLDEX THERAPEUTICS INC NEW$37,635,000
+33.1%
2,062,200
-5.5%
0.36%
+22.0%
AFMD  AFFIMED N V$36,051,000
-1.6%
5,814,6300.0%0.34%
-10.2%
MDT BuyMEDTRONIC INC$35,652,000
+36.0%
493,800
+16.7%
0.34%
+24.5%
 INCYTE CORPnote 4.750%10/0$35,309,000
+52.5%
4,242,0000.0%0.34%
+39.3%
ARRY BuyARRAY BIOPHARMA INC$34,282,000
+50.0%
7,247,700
+13.2%
0.33%
+37.2%
CAH BuyCARDINAL HEALTH INC$26,237,000
+26.4%
325,000
+17.3%
0.25%
+15.7%
F113PS  COVIDIEN PLCcall$25,570,000
+18.2%
250,0000.0%0.24%
+8.0%
LOXO  LOXO ONCOLOGY INC$25,566,000
-10.5%
2,175,8570.0%0.24%
-18.1%
KYTH NewKYTHERA BIOPHARMACEUTICALS I$25,070,000722,900
+100.0%
0.24%
PTLA  PORTOLA PHARMACEUTICALS INC$24,092,000
+12.0%
850,7000.0%0.23%
+2.2%
UNH BuyUNITEDHEALTH GROUP INC$23,756,000
+37.7%
235,000
+17.5%
0.23%
+26.1%
VRX BuyVALEANT PHARMACEUTICALS INTL$23,184,000
+28.0%
162,000
+17.4%
0.22%
+17.5%
TEVA SellTEVA PHARMACEUTICAL INDS LTDadr$23,004,000
-35.4%
400,000
-39.6%
0.22%
-40.9%
MRTX  MIRATI THERAPEUTICS INC$21,613,000
+5.8%
1,167,0000.0%0.21%
-2.8%
F113PS BuyCOVIDIEN PLC$21,602,000
+38.3%
211,200
+16.9%
0.21%
+26.4%
OSUR SellORASURE TECHNOLOGIES INC$20,062,000
-48.3%
1,978,500
-63.2%
0.19%
-52.6%
FWP NewFORWARD PHARMA A/Ssponsored adr$20,009,000960,600
+100.0%
0.19%
AMAG BuyAMAG PHARMACEUTICALS INC$19,989,000
+296.4%
469,000
+196.8%
0.19%
+260.4%
 FLUIDIGM CORP DELnote 2.750% 2/0$19,851,000
+6.5%
21,935,0000.0%0.19%
-2.6%
RCPT NewRECEPTOS INC$19,124,000156,100
+100.0%
0.18%
JAZZ  JAZZ PHARMACEUTICALS PLC$18,829,000
+2.0%
115,0000.0%0.18%
-6.7%
ANTM NewANTHEM INC$17,443,000138,800
+100.0%
0.17%
XNCR BuyXENCOR INC$16,778,000
+114.9%
1,046,000
+24.7%
0.16%
+95.1%
MRGE  MERGE HEALTHCARE INC$16,477,000
+61.8%
4,628,5000.0%0.16%
+48.1%
PCRX SellPACIRA PHARMACEUTICALS INC$15,604,000
-32.3%
176,000
-26.0%
0.15%
-38.2%
SAGE SellSAGE THERAPEUTICS INC$15,091,000
-10.8%
412,335
-23.3%
0.14%
-18.6%
 VOLCANO CORPORATIONnote 1.750%12/0$14,865,000
+14.4%
15,000,0000.0%0.14%
+4.4%
SVA  SINOVAC BIOTECH LTD$14,756,000
+8.7%
2,821,5000.0%0.14%
-0.7%
BMY SellBRISTOL MYERS SQUIBB COcall$14,758,000
-3.9%
250,000
-16.7%
0.14%
-11.9%
ROKA  ROKA BIOSCIENCE INC$14,202,000
-56.1%
3,220,4290.0%0.14%
-59.8%
HZNP BuyHORIZON PHARMA PLC$13,857,000
+25.9%
1,075,000
+20.0%
0.13%
+14.8%
STJ SellST JUDE MED INC$11,250,000
-81.7%
173,000
-83.1%
0.11%
-83.2%
SHPG SellSHIRE PLCcall$10,627,000
-95.7%
50,000
-94.7%
0.10%
-96.0%
MEIP BuyMEI PHARMA INC$10,353,000
-22.0%
2,424,500
+26.0%
0.10%
-28.8%
PTX  PERNIX THERAPEUTICS HLDGS IN$10,075,000
+22.3%
1,073,0000.0%0.10%
+11.6%
AGEN SellAGENUS INC$9,693,000
-13.1%
2,441,500
-31.9%
0.09%
-19.8%
MDXG BuyMIMEDX GROUP INC$9,648,000
+70.1%
836,800
+5.2%
0.09%
+55.9%
ABT BuyABBOTT LABS$9,499,000
+26.9%
211,000
+17.2%
0.09%
+16.7%
SLXP  SALIX PHARMACEUTICALS INC$9,425,000
-26.4%
82,0000.0%0.09%
-32.8%
AEGR NewAEGERION PHARMACEUTICALS INCcall$8,376,000400,000
+100.0%
0.08%
AET BuyAETNA INC NEW$8,350,000
+28.9%
94,000
+17.5%
0.08%
+17.6%
ALIM  ALIMERA SCIENCES INC$8,310,000
+2.2%
1,500,0000.0%0.08%
-7.1%
RDHL  REDHILL BIOPHARMA LTDsponsored ads$8,075,000
+1.2%
605,8000.0%0.08%
-7.2%
NewOREXIGEN THERAPEUTICS INCnote 2.750%12/0$7,538,0007,500,000
+100.0%
0.07%
GEVA SellSYNAGEVA BIOPHARMA CORP$7,219,000
-5.5%
77,800
-30.0%
0.07%
-13.8%
XOMA SellXOMA CORP DEL$7,180,000
-30.0%
2,000,000
-17.9%
0.07%
-35.5%
ARQL  ARQULE INC$6,956,000
+8.9%
5,702,0000.0%0.07%
-1.5%
NewINCYTE CORPnote 1.250%11/1$6,558,0004,250,000
+100.0%
0.06%
RGLS NewREGULUS THERAPEUTICS INC$6,416,000400,000
+100.0%
0.06%
NewINCYTE CORPnote 0.375%11/1$6,425,0004,250,000
+100.0%
0.06%
DVA BuyDAVITA HEALTHCARE PARTNERS I$5,756,000
+21.1%
76,000
+16.9%
0.06%
+10.0%
ASPX NewAUSPEX PHARMACEUTICALS INC$4,912,00093,600
+100.0%
0.05%
SUPN  SUPERNUS PHARMACEUTICALS INC$4,814,000
-4.5%
580,0000.0%0.05%
-13.2%
IPXL SellIMPAX LABORATORIES INCcall$4,752,000
-19.8%
150,000
-40.0%
0.04%
-27.4%
BSX BuyBOSTON SCIENTIFIC CORP$4,240,000
+32.1%
320,000
+17.8%
0.04%
+20.6%
NLNK  NEWLINK GENETICS CORPcall$3,975,000
+85.6%
100,0000.0%0.04%
+72.7%
FATE  FATE THERAPEUTICS INC$3,485,000
-1.4%
692,9000.0%0.03%
-10.8%
SGEN NewSEATTLE GENETICS INCput$3,213,000100,000
+100.0%
0.03%
CRIS  CURIS INC$2,925,000
+6.4%
1,950,1000.0%0.03%
-3.4%
DSCI  DERMA SCIENCES INC$2,793,000
+11.8%
300,0000.0%0.03%
+3.8%
UPI  UROPLASTY INC$2,809,000
-17.6%
1,363,5000.0%0.03%
-25.0%
CNXR NewCONNECTURE INC$2,724,000302,300
+100.0%
0.03%
NSPR  INSPIREMD INC$2,449,000
-64.7%
3,150,0000.0%0.02%
-68.1%
ACHN  ACHILLION PHARMACEUTICALS IN$1,936,000
+22.8%
158,0000.0%0.02%
+18.8%
BLRX  BIOLINERX LTDsponsored adr$1,839,000
+5.2%
1,135,0000.0%0.02%0.0%
SGMO NewSANGAMO BIOSCIENCES INCcall$1,521,000100,000
+100.0%
0.02%
BONE  BACTERIN INTL HLDGS INC$1,441,000
-32.3%
475,4390.0%0.01%
-36.4%
CEMP NewCEMPRA INC$1,176,00050,000
+100.0%
0.01%
 ENDOLOGIX INCnote 2.250%12/1$980,000
+9.1%
1,000,0000.0%0.01%0.0%
 BIOMARIN PHARMACEUTICAL INCnote 1.500%10/1$611,000
+11.1%
500,0000.0%0.01%0.0%
 BIOMARIN PHARMACEUTICAL INCnote 0.750%10/1$593,000
+12.1%
500,0000.0%0.01%0.0%
AMRN  AMARIN CORP PLCspons adr new$392,000
-10.1%
400,0000.0%0.00%
-20.0%
BIOD  BIODEL INC$279,000
-20.3%
209,7000.0%0.00%
-25.0%
SNSS ExitSUNESIS PHARMACEUTICALS INCcall$0-350,000
-100.0%
-0.03%
CSII ExitCARDIOVASCULAR SYS INC DEL$0-170,000
-100.0%
-0.04%
LLY ExitLILLY ELI & CO$0-112,000
-100.0%
-0.08%
MYL ExitMYLAN INC$0-169,100
-100.0%
-0.08%
SNSS ExitSUNESIS PHARMACEUTICALS INC$0-1,200,000
-100.0%
-0.09%
FPRX ExitFIVE PRIME THERAPEUTICS INC$0-1,075,400
-100.0%
-0.13%
V107SC ExitWELLPOINT INC$0-118,500
-100.0%
-0.15%
PBYI ExitPUMA BIOTECHNOLOGY INCcall$0-60,000
-100.0%
-0.15%
GWPH ExitGW PHARMACEUTICALS PLCads$0-221,000
-100.0%
-0.19%
DRTX ExitDURATA THERAPEUTICS INC$0-1,785,714
-100.0%
-0.24%
AMBI ExitAMBIT BIOSCIENCES CORP$0-1,490,769
-100.0%
-0.24%
AMGN ExitAMGEN INCcall$0-200,000
-100.0%
-0.29%
COO ExitCOOPER COS INCcall$0-200,000
-100.0%
-0.32%
SLXP ExitSALIX PHARMACEUTICALS INCcall$0-200,000
-100.0%
-0.33%
QGEN ExitQIAGEN NV$0-1,700,000
-100.0%
-0.40%
ARWR ExitARROWHEAD RESH CORP$0-5,178,200
-100.0%
-0.80%
CFN ExitCAREFUSION CORP$0-4,756,000
-100.0%
-2.25%
Other managers

Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):

Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2015-02-13
Signatures

The EDGAR filing(s) were signed by:

About Orbimed Advisors

Orbimed Advisors is a leading healthcare-focused investment firm that manages over $16 billion in assets. The firm was founded in 1998 by Samuel Isaly, who has over 50 years of experience in the healthcare industry. Isaly is widely regarded as a pioneer in the field of healthcare investing and has been recognized for his contributions to the industry by numerous organizations.

Orbimed Advisors has a team of over 100 professionals, including investment professionals, research analysts, and operational experts. The firm has offices in New York, San Francisco, Shanghai, and Mumbai, and invests in companies across the healthcare spectrum, including biotechnology, pharmaceuticals, medical devices, and healthcare services.

The firm's investment philosophy is based on a deep understanding of the healthcare industry and a rigorous approach to due diligence. Orbimed Advisors seeks to identify companies with innovative technologies and strong management teams that have the potential to transform the healthcare landscape.

Orbimed Advisors has a strong track record of success, with numerous successful investments in companies such as Juno Therapeutics, Spark Therapeutics, and Kite Pharma. The firm's leadership team, which includes CEO Sven Borho, COO Jonathan Silverstein, and Chief Investment Officer Carl Gordon, has decades of experience in the healthcare industry and is widely respected for their expertise and insights.

Overall, Orbimed Advisors is a leading healthcare investment firm that has a proven track record of success and a deep understanding of the healthcare industry. Investors looking to gain exposure to the healthcare sector may want to consider Orbimed Advisors as a potential investment opportunity.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
BIOGEN INC42Q3 20235.0%
VERTEX PHARMACEUTICALS INC42Q3 20233.7%
THERMO FISHER SCIENTIFIC INC42Q3 20233.2%
SINOVAC BIOTECH LTD41Q3 20237.2%
NEUROCRINE BIOSCIENCES INC41Q3 20232.7%
BOSTON SCIENTIFIC CORP40Q3 20235.6%
BRISTOL-MYERS SQUIBB CO40Q2 20235.2%
AMGEN INC40Q3 20235.5%
INTUITIVE SURGICAL INC40Q3 20233.8%
GILEAD SCIENCES INC39Q3 20235.5%

View Orbimed Advisors's complete holdings history.

Latest significant ownerships (13-D/G)
Orbimed Advisors Q4 2014 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Ikena Oncology, Inc.September 21, 20232,189,1115.2%
Galecto, Inc.September 18, 2023749,5572.8%
PMV Pharmaceuticals, Inc.August 23, 20236,563,07713.5%
Gracell Biotechnologies Inc.August 11, 20237,641,5318.0%
Xtant Medical Holdings, Inc.August 03, 202373,114,59256.7%
Turnstone Biologics Corp.July 24, 20233,099,26513.4%
Prelude Therapeutics IncMay 24, 202315,716,64228.6%
VectivBio Holding AGMay 24, 20235,156,5617.7%
Fusion Pharmaceuticals Inc.May 16, 20232,930,6704.6%
Verona Pharma plcMay 16, 20233,777,7784.8%

View Orbimed Advisors's complete significant-ownership history.

Latest filings
TypeFiled
42024-04-26
42024-04-23
42024-04-18
42024-04-15
3/A2024-04-12
SC 13D/A2024-04-12
42024-04-05
SC 13D/A2024-04-04
32024-04-03
SC 13D2024-03-28

View Orbimed Advisors's complete filings history.

Compare quarters

Export Orbimed Advisors's holdings